Bioactive N-phenylimidazole derivatives

Current Chemical Biology

Volumn 3, Issue 1, 2009, Pages 65-88

  Pastor, Isidro M ^a   Yus, Miguel ^a  

^a UNIVERSITY OF ALICANTE   (Spain)

Author keywords

Biological activity; Imidazole derivatives; Imidazole synthesis; Pharmacological activity

Indexed keywords

1 (1 PHENYLIMIDAZOL 2 YL) 3 (4 PYRIDYL)PROPENONE; 1 PHENYL 4 IMIDAZOLECARBOXAMIDE; 1 PHENYLIMIDAZOLE; 1 PHENYLIMIDAZOLE DERIVATIVE; 1,4 DIPHENYL 2 IMIDAZOLYLPHENYLMETHANONE; 1,5 DIARYLIMIDAZOLE DERIVATIVE; 2 ALKOXYIMIDAZOLE DERIVATIVE; 2 ARYL 1 PHENYL 4 TRIFLUROMETHYLIMIDAZOLE DERIVATIVE; 2 SULFINYLIMIDAZOLE DERIVATIVE; 3 IMIDAZOLYL 2 ALKOXYPROPANOIC ACID DERIVATIVE; 5 ETHYL 1,2,4 TRIS(4 HYDROXYPHENYL)IMIDAZOLE; 5 INDOLYLIMIDAZOLE DERIVATIVE; ARYLISOXAZOLYLMIDAZOLE DERIVATIVE; BIIMIDAZOLE DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CLOZAPINE; COMBRETASTATIN A4; DIARYLIMIDAZOLE; IMIDAZOLE; IMIDAZOLE DERIVATIVE; IMIDAZOLEACETAMIDE DERIVATIVE; IMIDAZOLECARBOXAMIDE DERIVATIVE; INDOLE DERIVATIVE; N PHENYLIMIDAZOLE DERIVATIVE; PHENYLIMIDAZOLE 5 CARBOXYLATE DERIVATIVES; PIPERAZINE; RHODANINE; RIMONABANT; SPIROINDOLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHMA; DRUG ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; NONHUMAN; OBESITY; POLLAKISURIA; PRIORITY JOURNAL; REVIEW; THROMBOSIS; URINE INCONTINENCE;

EID: 65649141318     PISSN: 18723136     EISSN: None     Source Type: Journal    
DOI: 10.2174/2212796810903010065     Document Type: Review

References (203)

1. Nebert DW, Gonzalez FJ. P450 genes: structure, evolution, and regulation. Annu Rev Biochem 1987; 56: 945-93.
2. Murray M. Mechanism of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents. Drug Metab Rev 1987; 18: 55-81.
3. Kobayashi Y, Matsuura Y, Kotani E, et al. Structural requirements for the induction of hepatic microsomal cytochrome P450 by imidazole- and pyridine-containing compounds in rats. J Biochem 1993; 114: 697-701.
4. Lipscomb JD. Electron paramagnetic resonance detectable states of cytochrome P-450cam. Biochemistry 1980; 19: 3590-9.
5. -) complex of cytochrome P-450cam. Effects of d-camphor and putidaredoxin on the iron-ligand structure. J Am Chem Soc 1989; 111: 7707-10.
6. 1H NMR study. J Am Chem Soc 1994; 116: 4866-73.
7. Wilkinson CF, Hetnarski K, Denison MS, Guengerich FP. Selectivity of 1-phenylimidazole as a ligand for cytochrome P-450 and as an inhibitor for microsomal oxidation. Biochem Pharmacol 1983; 32: 997-1003.
8. Harris DL, Chang Y-T, Loew GH. Molecular dynamics simulations of phenylimidazole inhibitor complexes of cytochrome P450cam. Mol Eng 1995; 5: 143-56.
9. Poulos TL, Howard AJ. Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P-450cam. Biochemistry 1987; 26: 8165-74.
10. Smith SJ, Munro AW, Smith WE. Resonance Raman scatterin of cytochrome P450 BM3 and effect of imidazole inhibitors. Biopolymers 2003; 70: 620-7.
11. de Graff C, Pospisil P, Pos W, Folkers G, Vermeulen NPE. Binding mode prediction of cytochrome P450 and thymidini kinase protein-ligand complexes by consideration of water and rescoring in automated docking. J Med Chem 2005; 48: 2308-18.
12. 0 electronic spectrum of jet cooled 1-phenylimidazole. J Chem Phys 2004; 121: 12421-7.
13. Mó O, Yáñez M, Roux MV, et al. Enthalpies of formation of N- substituted pyrazoles and imidazoles. J Phys Chem A 1999; 103: 9336-44.
14. Ribeiro da Silva MAV, Ribeiro da Silva MDMC, Matos MAR, et al. Enthalpies of combustion, heat capacities, and enthalpies of vaporisation of 1-phenylimidazole and 1-phenylpyrazole. J Chem Thermodyn 2000; 32: 237-45.
15. Poulos TL, Finzel BC, Howard AJ. Crystal structure of substrate-free Pseudomonas putida cytochrome P-450. Biochemistry 1986; 25: 5314-22.
16. Harris D, Loew G. Comparative study of free energies of solvation of phenylimidazole inhibitors of cytochrome P450cam by free energy simulation, AMSOL and Poisson Boltzmann methods. J Comput Chem 1996; 17: 273-88.
17. Trnka MJ, Doneanu CE, Trager WF. Photoaffinity labeling of P450cam by an imidazole-tethered benzophenone probe. Arch Biochem Biophys 2006; 445: 95-107.
18. Anari MR, Khan S, O'Brien PJ. The involvement of cytochrome P450 peroxidase in the metabolic bioactivation of cumene hydroperoxide by isolated rat hepatocytes. Chem Res Toxicol 1996; 9: 924-31.
19. Khan KK, Halpert JR. 7-Benzyloxyquinoline oxidation by P450eryF A245T: finding of a new fluorescent substrate probe. Chem Res Toxicol 2002; 15: 806-14.
20. Roberts GA, Celik A, Hunter DJB, et al. A self-sufficient cytochrome P450 with a primary structural organization that includes a flavin domain and a [2Fe-2S] redox center. J Biol Chem 2003; 278: 48914-20.
21. Lu P, Alterman MA, Chaurasia CS, Bambal RB, Hanzlik RP. Heme-coordinating analogs of lauric acid as inhibitors of fatty acid ω-hydroxylation. Arch Biochem Biophys 1997; 337: 1-7.
22. Dierks EA, Davis SC, Ortiz de Montellano PR. Glu-320 and Asp-323 are determinants of the CYP4A1 hydroxylation regiospecificity and resistance to inactivation by 1-aminobenzotriazole. Biochemistry 1998; 37: 1839-47.
23. Murray M, Wilkinson CF. Interactions of nitrogen heterocycles with cytochrome P-450 and monooxygenase activity. Chem-Biol Interact 1984; 50: 267-75.
24. Spatzenegger M, Wang Q, He YQ, Wester MR, Johnson EF, Halpert JR. Amino acid residues critical for differencial inhibition of CYP2B4, CYP2B5, and CYP2B1 by phenylimidazoles. Mol Pharmacol 2001; 59: 475-85.
25. Muralidhara BK, Negi S, Chin CC, Braun W, Halpert JR. Conformational flexibility of mammalian cytochrome P450 2B4 in binding imidazole inhibitors with different ring chemistry and side chains. J Biol Chem 2006; 281: 8051-61.
26. Domenech P, Barry CE, III, Cole ST. Mycobacterium tuberculosis in the post-genomic age. Curr Op Microbiol 2001; 4: 28-34.
27. McLean KJ, Warman AJ, Seward HE, et al. Biophysical characterization of the sterol demethylase P450 from Mycobacterium tuberculosis, its cognate ferredoxin, and their interactions. Biochemistry 2006; 45: 8427-43.
28. Feldman PL, Griffith OW, Stuerh DJ. The surprising life of nitric oxide. Chem Eng News 1993; 71: 26-38.
29. Kerwin JF Jr, Lancaster JR Jr, Feldman PL. Nitric oxide: a new paradigm for second messengers. J Med Chem 1995; 38: 4343-62.
30. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994; 298: 249-58.
31. Masters BSS, McMillan K, Sheta EA, Nishimura JS, Roman LJ, Martasek P. Cytochromes P450. 3. Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: structure studies of a cysteine thiolate-liganded heme protein that hydroxylates L-arginine to produce NO as a cellular signal. FASEB J 1996; 10: 552-8.
32. White KA, Marletta MA. Nitric oxide synthase is a cytochrome P-450 type hemoprotein. Biochemistry 1992; 31: 6627-31.
33. Berka V, Chen P-F, Tsai A-L. Spatial relationship between L-arginine and heme binding sites of endothelial nitric-oxide synthase. J Biol Chem 1996; 271: 33293-300.
34. Wolff DJ, Datto GA, Samaotovicz RA, Tempsick RA. Calmodulin-dependent nitric oxide synthase: mechanism of inhibition by imidazole and phenylimidazoles. J Biol Chem 1993; 268: 9425-9.
35. Wolff DJ, Lubeskie A, Umansky S. The inhibition of the constitutive bovine endothelial nitric oxide synthase by imidazole and indazole agents. Arch Biochem Biophys 1994; 314: 360-6.
36. McMillan K, Masters BSS. Optical difference spectrophotometry as a probe of rat brain nitric oxide synthase heme-substrate interaction. Biochemistry 1993; 32: 9875-80.
37. Roman LJ, Sheta EA, Martasek P, Gross SS, Liu Q, Masters BSS. High-level expression of functional rat neuronal nitric oxide synthase in Escherichia coli. Proc Natl Acad Sci USA 1995; 92: 8428-32.
38. Chen P-F, Tsai AL, Wu KK. Cysteine 184 of endothelial nitric oxide synthase is involved in heme coordination and catalytic activity. J Biol Chem 1994; 269: 25062-6.
39. Berka V, Palmer G, Chen PF, Tsai AL. Effects of various imidazole ligands on heme conformation in endothelial nitric oxide synthase. Biochemistry 1998; 37: 6136-44.
40. Chabin RM, McCauley E, Calaycay JR, et al. Active-site structure analysis of recombinant human inducible nitric oxide synthase using imidazole. Biochemistry 1996; 35: 9567-75.
41. Chen PF, Berka V, Tsai AL, Wu KK. Effects of Asp-369 and Arg-372 mutations on heme environment and function in human endothelial nitric-oxide synthase. J Biol Chem 1998; 273: 34164-70.
42. Dick JMC, Lefebvre RA. Influence of different classes of NO synthase inhibitors in the pig gastric fundus. Naunyn-Schmiedeberg's Arch Pharmacol 1997; 356: 488-94.
43. Sennequier N, Wolan D, Stuerh DJ. Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. J Biol Chem 1999; 274: 930-8.
44. Mugford CA, Carfagna MA, Kedderis GL. Furan-mediated uncoupling of hepatic oxidative phosporylation in Fischer-344 rats: an early even in cell death. Toxicol Appl Pharmacol 1997; 144: 1-11.
45. 14C]furan in the male F-344 rat. J Toxicol Environ Health 1991; 34: 245-57.
46. Chen LJ, Hecht SS, Peterson LA. Identification of cis-2-butene-1,4-dial as a microsomal metabolite of furan. Chem Res Toxicol 1995; 8: 903-6.
47. 1 mice. Fundam Appl Toxicol 1993; 20: 302-15.
48. 1 mouse and F-344 rat hepatocytes. Toxicol Appl Pharmacol 1998; 149: 217-25.
49. Hirashima A, Pan C, Kuwano E, Taniguchi E, Eto M. Three-dimensional pharmacophore hypotheses for the locust neuronal octopamine receptor (OAR3). Part 2: Agonists. Bioorg Med Chem 1999; 7: 1437-43.
50. Hirashima A, Nagata T, Pan C, Kuwano E, Taniguchi E, Eto M. Three-dimensional molecular field analyses of octopaminergic agonists anda antagonists for the locust neuronal octopamine recpetor class 3. J Mol Graphics Mod 1999; 17: 198-206.
51. Schilling S, Niestroj AJ, Rahfeld J-U, et al. Identification of Human Glutaminyl Cyclase as a Metalloenzyme. J Biol Chem 2003; 278: 49773-9.
52. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40: 581-616.
53. Vashishtha SC, Hawes EM, McKay G, MacCann DJ. Synthesis and identification of the quaternary ammonium-linked glucuronide of 1-phenylimidazole in human liver microsomes and investigation of the human UDP-glucuronosyltransferases involved. Drug Metab Dispos 2000; 28: 1009-13.
54. Vashishtha SC, Hawes EM, McKay G, MacCann DJ. Quaternary ammonium-linked glucuronidation of 1-substituted imidazoles: studies of human UDP-glucuronosyltransferases involved and substrate sepecificities. Drug Metab Dispos 2001; 29: 1290-5.
55. Vashishtha SC, Hawes EM, MacCann DJ, Ghosheh O, Hogg L. Quaternary ammonium-linked glucuronidation of 1-substituted imidazoles by liver microsomes: interspecies differences and structure-metabolism relationships. Drug Metab Dispos 2002; 30: 1070-6.
56. Muegge I, Martin YC. A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J Med Chem 1999; 42: 791-804.
57. Muegge I, Martin YC, Hajduk PJ, Fesik SW. Evaluation of PMF scoring in docking weak ligands to the FK506 binding protein. J Med Chem 1999; 42: 2498-503.
58. +)-ATPase. Nature 1981; 290: 159-61.
59. +-ATPase inhibitors. J Med Chem 1996; 39: 596-604.
60. Lee Y, Martasek P, Roman LJ, Masters BSS, Silverman RB. Imidazole-containing amino acids as selective inhibitors of nitric oxide synthases. Bioorg Med Chem 1999; 7: 1941-51.
61. Koen YM, Williams TD, Hanzlik RP. Identification of three protein targets for reactive metabolites of bromobenzene in rat liver cytosol. Chem Res Toxicol 2000; 13: 1326-35.
62. Koen YM, Hanzlik RP. Identification of seven proteins in the endoplasmic reticulum as targets for reactive metabolites of bromobenzene. Chem Res Toxicol 2002; 15: 699-706.
63. t-arylhistidine derivatives via direct N-arylation. Bioorg Med Chem Lett 2004; 14: 1637-40.
64. Black WC. Selective cyclooxygenase-2 inhibitors. Annu Rep Med Chem 2004; 39: 125-38.
65. Tuyen TN, Sin K-S, Kim HP, Park H. Synthesis and antiinflammatory activity of 1,5-diarylimidazoles. Arch Pharm Res 2005; 28: 1013-8.
66. Handler N, Jaeger W, Kuen-Krismer B, Erker T. Cyclooxygenase-1 and cyclooxygenase-2 inhibition of novel 1,2-disubstituted imidazoles. Arch Pharm (Weinheim, Ger) 2005; 338: 602-4.
67. Wang L, Woods KW, Li Q, et al. Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation. J Med Chem 2002; 45: 1697-711.
68. Bellina F, Cauteruccio S, Mannina L, Rossi R, Viel S. Regioselective synthesis of 1,5-diaryl-1H-imidazoles by palladium-catalyzed direct arylation of 1-aryl-1H-imidazoles. J Org Chem 2005; 70: 3997-4005.
69. Mailliet P, Le Brun A, Thompson F, Gilles T. Preparation of N-arylhteroaryls, in particular N-phenylpiperazinyl methanones, as inhibitors of tubulin polymerization and their compositions for treatment of cancer. WO 2004108685. 2004; Chem Abstr 2005; 142: 38281.
70. Catalano JG, Deaton DN, Long ST, et al. Design of small molecule ketoamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett 2004; 14: 719-22.
71. Tavares FX, Boncek V, Deaton DN, et al. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin K. J Med Chem 2004; 47: 588-99.
72. Tavares FX, Deaton DN, Miller AB, Miller LR, Wright LL, Zhou HQ. Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K. J Med Chem 2004; 47: 5049-56.
73. Catalano JG, Deaton DN, Miller AB, Tavares FX. Preparation of cycloalkyl α-ketoamide derivates as cathepsin K inhibitors. WO 2003062192. Chem Abstr 2003; 139: 3839.
74. Tavares FX, Deaton DN, Miller LR, Wright LL. Ketoamide-Based Inhibitors of Cysteine Protease, Cathepsin K: P3 Modifications. J Med Chem 2004; 47: 5057-68.
75. Fleisch H. From polyphosphates to bisphosphonates and their role in bone and calcium metabolism. In: Schröder HC, Müller WEG, editors. Progress in molecular and subcellular biology. Berlin: Springer-Verlag, 1999. pp. 197-216.
76. Wildler L, Jaeggi KA, Glatt M, et al. Highly potent geminal bisphosphonates. From Pamidronate disodium (Aredia) to Zoledronic acid (Zometa). J Med Chem 2002; 45: 3721-38.
77. Kotsikorou E, Oldfield E. A quantitative structure-activity relationship and pharmacophore modeling investigation of aryl-X and heterocyclic bisphosphonates as bone resorption agents. J Med Chem 2003; 46: 2932-44.
78. 3 receptor drugs. Nat Rev Drug Dis 2005; 4: 107-20.
79. 3 receptor antagonists with imidazole, thioimidazole and thioimidazoline polar groups in the side chain. Inflamm Res 2000; 49: S62-S3.
80. 4 antagonists. WO 9925710. 1999; Chem Abstr 1999; 131: 5257.
81. A α5 receptor ligands for the treatment of cognitive disorder and Alzheimer's disease. WO 2007074078. Chem Abstr 2007; 147: 3428.
82. A receptors. J Med Chem 2006; 49: 1855-66.
83. Yuan J, Wasley JWF. Preparation of 1-substituted aminomethylimidazole and aminomethylpyrrole derivatives as dopamine D3 and D4 ligands. US 5478934. 1995; Chem Abstr 1996; 124: 232458.
84. Yuan J, Wasley JWF. Preparation of 1-phenyl-3-(piperidinomethyl)imidazoles and analogs as dopamine receptor subtype specific ligands. WO 9616057. 1996; Chem Abstr 1996; 125: 114629.
85. Grant EB, Guiadeen D, Baum EZ, et al. The synthesis and SAR of rhodanines as novel class C β-lactamase inhibitors. Bioorg Med Chem Lett 2000; 10: 2179-82.
86. Gao Y-d, Macneil DJ, Yang L, et al. Preparation of spiroindolines as Y5 receptor antagonists. WO 2000027845. 2000; Chem Abstr 2000; 132: 334474.
87. Shenvi A, Jacobs RT, Miller SC, Ohnmacht CJ Jr, Vaele CA. Preparation of antiasthamtic heterocyclic neurokinin A receptor antagonists. EP 680962. 1995; Chem Abstr 1996; 124: 202248.
88. Alanine A, Buettelmann B, Heitz Neidhart MP, Jaeschke G, Pinard E, Wyler R. Preparation of imidazole derivatives as NMDA (N-methyl-D-aspartate) receptor subtype 2B selective blockers. WO 2002060877. 2002; Chem Abstr 2002; 137: 154932.
89. Allerton CMN, Blagg J, Bunnage ME, Steele J. Preparation of substituted imidazoles as TAFIa inhibitors. WO 2002014285. 2002; Chem Abstr 2002; 136: 184120.
90. Allerton CMN, Bull DJ, Bunnage ME, Maguire RJ, Steele J. Preparation of 3-(imidazolyl)-2-alkoxypropanoic acids as selective TAFIa inhibitors for treating thrombotic and other conditions associated with fibrin deposition. WO 2003061652. 2003; Chem Abstr 2003; 139: 149631.
91. Allerton CMN, Bunnage ME, Mark E, Steele J. Preparation of 3-(imidazolyl)-2-aminopropanoic acids for use as TAFI-a inhibitors for the treatment of thrombotic diseases. WO 2003061653. 2003; Chem Abstr 2003; 139: 292496.
92. Devon RS, Anderson S, Teague PW, et al. The genomic organisation of the metabotropic glutamate receptor subtype 5 gene, and its association with schizophrenia. Mol Psychiatry 2001; 6: 311-4.
93. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. Expression of the human excitatory amino acid transporter 2 and me tabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Mol Brain Res 1998; 56: 207-17.
94. Glatthar R, Carcache D, Spanka C, Vranesic I-T, Troxler TJ. Preparation of bi-aryl amines as mGluR5 modulators for treating gastrointestinal, urinary tract, and nervous system disorders. WO 2007113276. 2007; Chem Abstr 2007; 147: 427343.
95. Yoshikawa S, Shinzawa-Itoh K, Nakashima R, et al. Redox-coupled crystal structural changes in bovine heart cytochrome c oxidase. Science 1998; 280: 1723-9.
96. Ostermeier C, Harrenga A, Ermler U, Michel H. Structure at 2.7 Å resolution of the Paracoccus denitrificans two-subunit cytochrome c oxidase complexed with an antibody FV fragment. Proc Natl Acad Sci USA 1997; 94: 10547-53.
97. Michel H. The mechanism of proton pumping by cytochrome c oxidase. Proc Natl Acad Sci USA 1998; 95: 12819-24.
98. a determination of 1-(o-hydroxyphenyl)imidazole carboxylic esters. J Chem Soc Perkin Trans 1 2000: 1217-21.
99. Elliott GI, Konopelski JP. Complete N-1 regiocontrol in the formation of N-arylimidazoles. Synthesis of the active site His-Tyr side chain coupled dipeptide of cytochrome c oxidase. Org Lett 2000; 2: 3055-7.
100. Chen B-C, Bednarz MS, Zhao R, et al. A new facile method for the synthesis of 1-arylimidazole-5-carboxylates. Tetrahedron Lett 2000; 41: 5453-6.
101. Maruyama T, Onda K, Hayakawa M, Takahashi T, Suzuki T, Matsui T. Preparation of amide-containing heterocyclic compounds for the treatment of diabetes. WO 9832742. 1998; Chem Abstr 1998; 129: 161556.
102. Fatheree PR, Jenkins TE, Linsell MS, Trapp SG, Verner EJ, Young WB. Preparation of amidinobenzimidazolylheterocycles and related compounds as anticoagulants. WO 9926941. 1999; Chem Abstr 1999; 131: 19007.
103. Cooke T, Ekwuru T, Hardy D, et al. Preparation of fungicinal nitrogen compounds. WO 2001011966. 2001; Chem Abstr 2001; 134: 174247.
104. Pikul S, Mieling GE, Mieling KK, et al. Preparation of biphenyldifluoroalkanoats and related compounds as metalloprtease inhibitors. US 2003139453. 2003; Chem Abstr 2003; 139: 117211.
105. Sato S, Aitani K, Kumakura S. Preparation of imidazoles having inhibitory activity against adhesion of synoviocyte to collagen and production of cytokine. JP 2003040888. 2003; Chem Abstr 2003; 138: 170234.
106. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. Engl J Med 1999; 340: 1888-99.
107. Navidpour L, Shadnia H, Shafaroodi H, Amini M, Dehpour AR, Shafiee A. Design, synthesis, and biological evaluation of substituted 2-alkylthio-1,5-diarylimidazoles as selective COX-2 inhibitors. Bioorg Med Chem 2007; 15: 1976-82.
108. Almansa C, Gonzalez C, Torres MC. Novel imidazoles with anti-inflammatory activity and their preparation and use. WO 2000023426. 2000; Chem Abstr 2000; 132: 308336.
109. Pawar VG, De Borggraeve WM, Robeyns K, Van Meervelt L, Compernolle F, Hoornaert G. Synthesis of 1,5-disubstituted 4-haloimidazoles from α-aminonitriles. Tetrahedron Lett 2006; 47: 5451-3.
110. Ochiai Y, Ishiyama T, Kanaya N. Preparation of 7-membered heterocyclic derivatives as platelet aggregation inhibitors. WO 2004089937. 2004; Chem Abstr 2004; 141: 350205.
111. Okayama T, Uoto K, Ishiyama T, et al. Preparation of azole compounds as platelet aggregation inhibitors. WO 2004094407. 2004; Chem Abstr 2004; 141: 395556.
112. 2-adrenoceptor antagonism in the anticataleptic properties of the atypical neuroleptic agent. Br J Pharmacol 1998; 124: 1550-6.
113. A receptors. J Med Chem 2002; 45: 4655-68.
114. A receptor of a series of substituted 1,2-diphenylimidazoles. J Med Chem 2005; 48: 2638-45.
115. George P, De Peretti D, Gibert JF, Mangane M, Roy J. 1,4-Diphenylimidazole-5-acetamide derivatives as GABAA agonists. FR 2759698. 1998; Chem Abstr 1998; 129: 302640.
116. Shishikura JI, Inami H, Kaku H, Tsutsumi R, Yamashita H, Ohno K. Preparation of acylazole derivatives as kainic acid neurocytotoxicity inhibitors. WO 2001032173. 2001; Chem Abstr 2001; 134: 326537.
117. Gardell SJ. Preparation of imidazole derivatives for promoting smoking cessation. WO 2005099705. 2005; Chem Abstr 2005; 143: 422349.
118. Smith RA, O'Connor SJ, Wirtz SN, et al. Imidazole-4-carboxamide derivatives, and their preparation and use for treatment of obesity. WO 2003040107. 2003; Chem Abstr 2003; 138: 385424.
119. Lange JHM, Stuivenberg HH, Van Vliet BJ. Preparation of 1H-imidazole derivatives for use as modulators in the treatment of disorders involving cannabinoid CB2 receptors. WO 2006087355. 2006; Chem Abstr 2006; 145: 271779.
120. Zelle R, Galullo VP, Mazdiyasni H. 1,2,5-Trisubstituted imidazoles as ion channel modulators. US 2005203159. 2005; Chem Abstr 2005; 143: 306315.
121. Kusama M, Watanabe T, Hosaka T, Kubota Y. Preparation of imidazole compounds as a large conductance calcium-activated K channel openers. WO 2006030977. 2006; Chem Abstr 2006; 144: 390913.
122. Kusama M, Watanabe T, Hosaka T, Kubota H. Preparation of imidazole derivatives as BK channel openers. JP 2007277230. 2007; Chem Abstr 2007; 147: 486443.
123. Hendrix M, Buchmueller A, Dottrich W, et al. Preparation of acylaminoimidazoles as cardiovascular agents. DE 102006001574. 2007; Chem Abstr 2007; 147: 166322.
124. Figueiredo JM, Câmara CA, Amarante EG, et al. Design and synthesis of novel potent antinociceptive agents: methyl-imidazolyl-N-acylhydrazone derivatives. Bioorg Med Chem 2000; 8: 2243-8.
125. Lima PC, Lima LM, da Silva KCM, et al. Synthesis and analgesic activity of novel N-acylarylhydrazones and isosters, derived from natural safrole. Eur J Med Chem 2000; 35: 187-203.
126. Cunha AC, Tributino JLM, Miranda ALP, Fraga CAM, Barreiro EJ. Synthesis and pharmacological evaluation of novel antinociceptive N-substituted-phenylimidazolyl-4-acylhydrazone derivatives. Farmaco 2002; 57: 999-1007.
127. 1 cannabinoid receptor antagonists. J Med Chem 2005; 48: 1823-38.
128. 1 agonists, partial agonists, or antagonists for treatment of psychiatric and neurological disorders. WO 2003027076. 2003; Chem Abstr 2003; 138: 287674.
129. Hagmann WK, Qi H, Shah SK. Substituted imidazoles as cannabinoid receptor modulators, their preparation, and their therapeutic use. WO 2003063781. 2003; Chem Abstr 2003; 139: 144003.
130. Williams DR, Lee MR, Song YA, Ko SK, Kim GH, Shin I. Synthetic small molecules that induce neurogenesis in skeletal muscle. J Am Chem Soc 2007; 129: 9258-9.
131. Cosman F, Lindsay R. Selective estrogen receptor modulators: clinical spectrum. Endocr Rev 1999; 20: 418-34.
132. Stauffer SR, Coletta CJ, Tedesco R, et al. Pyrazole ligands: structure-affinity/activity relationship and estrogen receptor-α-selective agonists. J Med Chem 2000; 43: 4934-47.
133. Gust R, Keilitz R, Schmidt K. Investigations of new lead structures for the design of selective estrogen receptor modulators. J Med Chem 2001; 44: 1963-70.
134. Mortensen DS, Rodriguez AL, Carlson KE, Sun J, Katzenellenbogen BS, Katzenellenbogen JA. Synthesis and biological evaluation of novel series of furans: ligands selective for estrogen receptor α. J Med Chem 2001; 44: 3838-48.
135. Mull ES, Sattigeri VJ, Rodriguez AL, Katzenellenbogen JA. Aryl cyclopentadienyl tricarbonyl rhenium complexes: novel ligands for the estrogen receptor with potential use as estrogen radiopharmaceuticals. Bioorg Med Chem 2002; 10: 1381-98.
136. Wiglenda T, Gust R. Structure-activity relationship study to understand the estrogen receptor-dependent gene activation of aryl- and alkyl-substituted 1H-imidazoles. J Med Chem 2007; 50: 1475-84.
137. Mjalli A, Sarshar S, Cao X, Bakir F. Preparation of heterocyclic compounds as modulators of proteins with phosphotyrosine recognition units. US 5753687. 1998; Chem Abstr 1998; 129: 27943.
138. Mjalli A, Sarshar S. Preparation of 1,2,4,5-tetrasubstituted imidazoles as modulators of multi-drug resistance. US 5700826. 1997; Chem Abstr 1998; 128: 88918.
139. Mjalli A, Sarshar S. Preparation of substituted imidazoles as modulators of multi-drug resistance. EP 812829. 1997; Chem Abstr 1998; 128: 75396.
140. Holloway RH, Dent J. Pathophysiology of gastroesophageal reflux. Lower esophageal sphincter dysfunction in gastroesophageal reflux disease. Gastroenterol Clin N Am 1990; 19: 517-35.
141. Bauer U, Brailsford W, Chhajlani V, et al. Preparation of imidazole derivatives as allossteric modulators of GABAB receptor for the treatment of gastrointestinal disorders. WO 2006001750. 2006; Chem Abstr 2006; 144: 108318.
142. B receptor modulators for the treatment of gastrointestinal disorders. WO 2007073300. 2007; Chem Abstr 2007; 147: 118230.
143. Bauer U, Brailsford W, Gustafsson L, Saxin M, Svensson T. Prepartion of imidazole derivatives for the treatment of gastrointestinal disorders. WO 2007073298. 2007; Chem Abstr 2007; 147: 118232.
144. Merritt JE, Hallam TJ, Brown AM, et al. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor. Br J Pharmacol 1991; 102: 251-9.
145. Wise H. The inhibitory effects of non-prostanoid prostacyclin mimetics on rat neutrophil function. Prostaglandins Leukot Essent Fatty Acids 1996; 54: 351-60.
146. Chow KBS, Wong YH, Wise H. Prostacyclin receptor-independent inhibition of phospholipase C activity by non-prostanoid prostacyclin mimetics. Br J Pharmacol 2001; 134: 1375-84.
147. Kam Y-W, Chow KBS, Wise H. Factors affecting prostacyclin receptor agonist efficacy in different cell types. Cell Signall 2001; 13: 841-7.
148. 3 receptor antagonists. WO 9931097. 1999; Chem Abstr 1999; 131: 44998.
149. 3 receptor antagonism and therapeutic uses. WO 2001064671. 2001; Chem Abstr 2001; 135: 226994.
150. 3 receptor antagonism and therapeutic uses. WO 2001064631. 2001; Chem Abstr 2001; 135: 226993.
151. Laufer S, Kotschenreuther D, Merckle P, Tollmann K, Striegel HG. Preparation of 2-thioimidazoles as immunomodulators and cytokine inhibitors. WO 2002066458. 2002; Chem Abstr 2002; 137: 185486.
152. Grimmett MR. Imidazoles. Sci Synth 2002; 12: 325-528.
153. Grimmett MR. Imidazole and benzimidazole synthesis. London: Academic 1997.
154. Kiyomori A, Marcoux J-F, Buchwald SL. An efficient copper-catalyzed coupling of aryl halides with imidazoles. Tetrahedron Lett 1999; 40: 2657-60.
155. Antilla JC, Baskin JM, Barder TE, Buchwald SL. Copper-diamine-catalyzed N-arylation of pyrroles, pyrazoles, indazoles, imidazoles, and triazoles. J Org Chem 2004; 69: 5578-87.
156. Guo X, Rao H, Fu H, Jiang Y, Zhao Y. An inexpensive and efficient copper catalyst for N-arylation of amines, amides and nitrogen-containing heterocycles. Adv Synth Catal 2006; 348: 2197-202.
157. Sreedhar B, Kumar KBS, Srinivas P, Balasubrahmanyam V, Venkanna GT. CuI/ L-histidine catalyzed N-arylation of heterocycles. J Mol Catal A Chem 2007; 265: 183-5.
158. 3. Synlett 2006: 2124-6.
159. 3: an improved protocol. Tetrahedron Lett 2006; 47: 5203-5.
160. Altman RA, Buchwald SL. 4,7-Dimethoxy-1,10-phenantroline: an excelent ligand for the Cu-catalyzed N-arylation of imidazoles. Org Lett 2006; 8: 2779-82.
161. Altman RA, Koval ED, Buchwald SL. Copper-catalyzed N-arylation of imidazoles and benzimidazoles. J Org Chem 2007; 72: 6190-9.
162. de Lange B, Lambers-Verstappen MH, Schimider-van de Vondervoort L, et al. Aromatic amination of aryl bromides catalysed by copper/ β-diketone catalysts: the effect of concentration. Synlett 2006: 3105-9.
163. Nandurkar NS, Bhanushali MJ, Bhor MD, Bhanage BM. N-Arylation of aliphatic, aromatic and heteroaromatic amines catalyzed by copper bis(2,2,6,6-tetramethyl-3,5-heptanedionate. Tetrahedron Lett 2007; 48: 6573-6.
164. Lv X, Bao W. A β-keto ester as novel, efficient, and versatile ligand for copper(I)-catalyzed C-N, C-O, and C-S coupling reaction. J Org Chem 2007; 72: 3863-7.
165. Verma AK, Singh J, Sankar VK, Chaudhary R, Chandra R. Benzotriazole: an excellent ligand for Cu-catalyzed N-arylation of imidazoles with aryl and heteroaryl halides. Tetrahedron Lett 2007; 48: 4207-10.
166. Cristau H-J, Cellier PP, Spindler J-F, Taillefer M. Highly efficient and mild copper-catalyzed N- and C-arylation with aryl bormides and iodides. Chem Eur J 2004; 10: 5607-22.
167. Xu L, Zhu D, Wu F, Wang R, Wan B. Mild and effcient copper-catalyzed N-arylation of alkylamines and N-H heterocycles using an oxime-phosphine oxide ligand. Tetrahedron 2005; 61: 6553-60.
168. Jerphagnon T, van Klink GPM, de Vries JG, van Koten G. Aminoarenethiolate-copper(I)-catalyzed amination of aryl bromides. Org Lett 2005; 7: 5241-4.
169. Zhu L, Cheng L, Zhang Y, Xie R-G, You J-S. Highly efficient copper-catalyzed N-arylation of nitrogen-containing heterocycles with aryl and heteroaryl halides. J Org Chem 2007; 72: 2737-43.
170. Taillefer M, Xia N, Ouali A. Efficient iron/copper co-catalyzed arylation of nitrogen nucleophiles. Angew Chem Int Ed 2007; 46: 934-6.
171. Kantam ML, Venkanna GT, Sridhar C, Kumar KBS. Copper fluorapatite catalyzed N-arylation of heterocycles with bromo and iodoarenes. Tetrahedron Lett 2006; 47: 3897-9.
172. Choudary BM, Sridhar C, Kantam ML, Venkanna GT, Sreedhar B. Design and evolution of copper apatite catalysts for N-arylation of heterocycles with chloro- and fluoroarenes. J Am Chem Soc 2005; 127: 9948-9.
173. Kantam ML, Rao BPC, Choudary BM, Reddy RS. A mild and efficient method for N-arylation of nitrogen heterocycles with aryl halides catalyzed by Cu(II)-NaY zeolite. Synlett 2006; 2195-8.
174. Reddy KR, Kumar NS, Sreedhar B, Kantam ML. N-Arylation of nitrogen heterocycles with aryl halides and arylboronic acids catalyzed by cellulose supported copper(0). J Mol Catal A Chem 2006; 252: 136-41.
175. Rout L, Jammi S, Punniyamurthy T. Novel CuO nanoparticle catalyzed C-N cross coupling of amines with iodobenzene. Org Lett 2007; 9: 3397-9.
176. Collman JP, Zhong M. An efficient diamine copper complex-catalyzed coupling of arylboronic acis with imidazoles. Org Lett 2000; 2: 1233-6.
177. 2-catalyzed coupling of
178. van Berkel SS, van den Hoogenband A, Terpstra JW, Tromp M, van Leeuwen PWNM, van Strijdonck GPF. Base-free anaerobic Cu(II) catalysed aryl-nitrogen bond formations. Tetrahedron Lett 2004; 45: 7659-62.
179. Collman JP, Zhong M, Zhang C, Costanzo S. Catalytic activities of Cu(II) complexes with nitrogen-chelatin bidentate ligands in the coupling of imidazoles with arylboronic acids. J Org Chem 2001; 66: 7892-7.
180. Lan JB, Chen LJ, Yu XQ, You JS, Xie RG. A simple copper salt catalysed the coupling of imidazole with arylboronic acids in protic solvent. Chem Commun 2004; 188-9.
181. 4] system. J Mol Catal A Chem 2006; 249: 201-6.
182. Kantam ML, Venkanna GT, Sridhar C, Sreedhar B, Choudary BM. An efficient base-free N-arylation of imidazoles and amines with arylboronic acids using copper-exchanged fluorapatite. J Org Chem 2006; 71: 9522-4.
183. Fedorov AY, Finet JP. N-Phenylation of azole derivatives by triphenylbismuth derivatives/cupric acetate. Tetrahedron Lett 1999; 40: 2747-8.
184. Kang SK, Lee SH, Lee D. Copper-catalyzed N-arylation of amines with hypervalent iodonium salts. Synlett 2000; 1022-4.
185. Liu Z, Larock RC. Facile N-arylation of amines and sulfonamides and O-arylation of phenols and arenecarboxylic acids. J Org Chem 2006; 71: 3198-209.
186. Torregrosa R, Pastor IM, Yus M. Isoprene-promoted lithiation of 1- phenylimidazole. ARKIVOC 2008; vii: 8-15.
187. Deng Y, Hlasta DJ. The synthesis of 2-substituted azoles bhrough a one-pot three-component reaction. Tetrahedron Lett 2002; 43: 189-92.
188. Deng Y, Hlasta DJ. Synthetic applications of azolium ylides to a traceless solid-phase synthesis of 2-substituted azoles. Org Lett 2002; 4: 4017-20.
189. Helal CJ, Lucas JC. A concise and regioselective synthesis of 1- alkyl-4-imidazolecarboxylate. Org Lett 2002; 4: 4133-4.
190. Huang WS, Yuan CY, Wang ZQ. Facile synthesis of 1-substituted 5-trifluoromethylimidazole-4-carboxylates. J Fluorine Chem 1995; 74: 279-82.
191. Huang WS, Yuan CY. Studies on organophosphorus compounds 92: a facile synthesis of 1-substituted 5-trifluoromehtylimidazole-4-phosphonates. Synthesis 1996; 511-13.
192. Dell'Erba C, Novi M, Petrillo G, Tavani C. Reactions of arylazo-sulfones with the conjugate bases of (tert-butoxycarbonyl)methyl and tosylmethyl isocyanide. Synthesis of substituted 1-arylimidazoles. Tetrahedron 1997; 53: 2125-36.
193. Bossio R, Marcaccini S, Pepino R. Studies on isocyanides and related compounds. Synthesis of 1-aryl-2-(tosylamino)-1H-imidazoles, a novel class of imidazole derivatives. J Org Chem 1996; 61: 2202-3.
194. Kanazawa C, Kamijo S, Yamamoto Y. Synthesis of imidazoles through the copper-catalyzed cross-cycloaddition between two different isocyanides. J Am Chem Soc 2006; 128: 10662-3.
195. Zhang C, Moran EJ, Woiwode TF, Short KM, Mjalli AMM. Synthesis of tetrasubstituted imidazoles via α-(N-acyl-N-alkylamino)-β-ketoamides on Wang Resin. Tetrahedron Lett 1996; 37: 751-4.
196. Kidwai M, Mothsra P. A one-pot synthesis of 1,2,4,5-tetraarylimidazoles using molecular iodine as an efficient catalyst. Tetrahedron Lett 2006; 47: 5029-31.
197. Liu J, Chen J, Zhao J, Zhao Y, Li L, Zhang H. A modified procedure for the synthesis of 1-arylimidazoles. Synthesis 2003; 2661-6.
198. Sarshar S, Siev D, Mjalli AMM. Imidazole libraries on solid support. Tetrahedron Lett 1996; 37: 835-8.
199. Chang JH, Lee KW, Nam DH, Kim WS, Shin H. Efficient synthesis of 1-substituted-5-hydroxymethylimidazole derivatives: clean oxidative cleavage of 2-mercapto group. Org Proc Res Dev 2002; 6: 674-6.
200. Pesch J, Harms K, Bach T. Preparation of axially chiral N,N'- diarylimidazolium and N-arylthiazolium salts and evaluation of their catalytic potential in the benzoin and in the intramolecular Stetter reaction. Eur J Org Chem 2004: 2025-35.
201. Frachey G, Crestini C, Bernini R, Saladino R, Mincione E. Oxidation of 2-mercaptobenzo heterazoles by dimethyldioxirane. A new method for a synthesis of C-2 substituted benzimidazole, benzoxazole, and benzothiazole derivatives. Heterocycles 1994; 38: 2621-30.
202. Wolfe DM, Schreiner PR. Facile conversion of amino acids into 1-alkyl imidazole-2-thiones, and their oxidative desulfurization to imidazoles with benzoyl peroxide. Synthesis 2007; 2002-8.
203. Xi N, Xu S, Cheng Y, Tasker AS, Hungate RW, Reider PJ. Regiocontrolled synthesis of N-substituted imidazoles. Tetrahedron Lett 2005; 46: 7315-9.